Allison Nowak, OD
Optometrist · Carmel, INNPI 1811032592
Payments from drug & device makers
What this record shows
14 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 54.4% of the total. Reporting peaked in 2022 at $3,183 and has fallen 82.4% since, to $561 in 2025. Among optometrist clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $99.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$4K
- Johnson & Johnson Vision Care, Inc.$983
- AbbVie$478
- Alcon$430
- Bausch & Lomb Americas Inc.$386
- Bausch & Lomb, A Division Of Bausch Health US, LLC$348
- plus $878 from 8 others
What the payments were for
- Consulting fees$4,17454%
- Food & beverage$3,50446%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 5 | $4,174 |
| Johnson & Johnson Vision Care, Inc. | 30 | $983 |
| AbbVie(2 entities) | 11 | $478 |
| Alcon | 7 | $430 |
| Bausch & Lomb Americas Inc. | 4 | $386 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $348 |
| Coopervision Inc. | 4 | $340 |
| Sun Pharmaceutical Industries Inc. | 5 | $198 |
| Tarsus Pharmaceuticals, Inc. | 2 | $145 |
| Oyster Point Pharma, Inc. | 1 | $122 |
| Aerie Pharmaceuticals, Inc. | 1 | $24 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
| Thea Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$1,243
- Acuvue$491
- INFUSE$360
- LUMIGAN$150
- Hydrus Microstent$130
- VUITY$125
- TYRVAYA$122
- VYZULTA$115
- MIEBO$113
- Precision 7$105
How this compares
$7,678 in reported general payments places this provider in the 95th percentile of 1,318 optometrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 51 | $43,065 |
| LumiganBimatoprost | 69 | $37,793 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $15,467 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $6,862 |
| Brimonidine Tartrate | 47 | $1,989 |
| Timolol Maleate | 184 | $1,827 |
| Loteprednol Etabonate | 16 | $1,773 |
| Prednisolone Acetate | 41 | $1,314 |
| Latanoprost | 85 | $1,128 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 20 | $715 |
| Memantine Hcl | 13 | $602 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 31 | $579 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 13 | $203 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $144 |
| Cephalexin | 11 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $478 | $96,325153 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $348 | $1,77316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,318 optometrist providers in Indiana.
Other optometrist in Carmel
- Jeremy CianoCarmel$12K
- Kylene PolhamusCarmel$7K
- Damon DierkerIndianapolis$707K
- Jason JedlickaBloomington$456K
- Kari RiinaFishers$308K
- Rhonda RobinsonIndianapolis$205K
- John CzajaMerrillville$189K
- Peter KollbaumBloomington$60K
- Ryan GustusBluffton$48K
- Steve VargoHighland$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.